Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with icotinib for slowly progressive non-small cell lung cancer after failure of icotinib
ChiCTR1800018857Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and icotinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: progression-free survival. Started Oct 2018; status: recruiting.
02
Drugs
Rivoceranibicotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800018857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018857.